Scientific Review Committee (SRC)

The R15 Research Enhancement Award is an NIH grant mechanism reserved for institutions that have not been major recipients of NIH research support — created to fund meritorious research at smaller, teaching-focused institutions while directly engaging students in hands-on research. R15 has two sub-programs: the Academic Research Enhancement Award (AREA), for undergraduate-focused institutions, and the Research Enhancement Award Program (REAP), for health professional schools and graduate schools that meet the same funding-history cap. “R15” and “AREA” are frequently used interchangeably in practice because AREA is by far the more commonly awarded of the two sub-programs, but they are not strictly synonymous — AREA is one of two R15 award types, not the whole activity code.

Institutional eligibility and the $6 million cap

The defining eligibility test is institutional NIH funding history, not the applicant’s own track record. An institution (or, for a multi-school university, its relevant non-health-professional components taken together) qualifies only if it has received no more than $6 million per year in total NIH support — direct and F&A/indirect costs combined — in 4 of the last 7 fiscal years. This is evaluated at the institutional level, so a single well-funded department cannot make an otherwise-eligible institution ineligible, and conversely a well-funded university cannot become eligible just because one department has little NIH history.

For AREA specifically, the institution must also grant baccalaureate degrees in NIH-relevant sciences and have undergraduate enrollment that exceeds graduate enrollment; health professional schools are not AREA-eligible (REAP exists for that population instead, along with other graduate-degree-granting institutions that meet the funding cap). Applicants must typically submit a signed institutional verification (commonly from the Provost’s office) confirming eligibility at the time of application.

The student-involvement requirement

R15/AREA is not just a smaller R01 — its stated purpose ties funding eligibility to an active teaching/training mission. NIH guidance requires that the research team be composed primarily of students (undergraduates, for AREA), working directly on the funded project alongside the PI rather than serving in a peripheral or purely observational role. This distinguishes R15 from research-only mechanisms like R33 or R01, where there is no comparable student-composition requirement.

Budget and project period

R15/AREA awards are capped: up to $375,000 in direct costs (plus applicable F&A/indirect costs) for a project period of up to 3 years. This figure has moved over time — some institute guidance still in circulation cites an older $300,000 ceiling — so applicants should confirm the current cap against the specific, currently-active Parent Announcement (PAR) they are applying under rather than relying on any single secondary source, including this one.

PI eligibility restrictions

A PI must hold a faculty appointment at an AREA/REAP-eligible institution and generally cannot simultaneously serve as PI (or the equivalent) on another active, substantial NIH research grant — an R01 held elsewhere at the time of award, for example, is disqualifying. NIH also limits a PI to one active AREA award at a time. These restrictions reinforce the mechanism’s purpose: building independent research capacity at institutions and for investigators who do not already have significant NIH support, rather than supplementing PIs who do.

Standard due dates

R15 uses its own position on NIH’s NIH Standard Due Dates calendar — February 25, June 25, and October 25, the same three dates for new, renewal, resubmission, and revision applications alike (unlike R01 or R21/R03, which offset new vs. resubmission dates by about a month). Applications are typically reviewed by a chartered NIH study section or a Special Emphasis Panel convened for AREA/REAP applications specifically.

Why NIH created this mechanism

NIH’s own framing is explicit: R15 exists to strengthen the research environment at institutions that provide baccalaureate (or, for REAP, graduate/health-professional) training but have not historically been substantial NIH grantees, and to expose students at those institutions to hands-on, competitively-funded research early in their training — a pipeline goal distinct from R15’s function as a funding mechanism. It is one of relatively few NIH activity codes where institutional funding history is itself a formal eligibility gate rather than just a review consideration.

Related terms and CASRAI resources

• R33 (NIH Exploratory/Developmental Grant) — a different small-scale NIH mechanism with no institutional funding-history cap or student-composition requirement.
• NIH Study Section — the peer-review panel type (chartered or Special Emphasis Panel) that reviews R15 applications.
• NIH Standard Due Dates — the full activity-code-by-activity-code due-date table, including R15’s February/June/October 25 dates.
• R21 vs. R03: NIH Exploratory Grant vs. Small Grant Program Compared — how two other small/early-stage NIH mechanisms differ from each other and, by extension, from R15’s eligibility-gated design.
• NIH Modular Budgets — budget-format mechanics for NIH applications generally, including which mechanisms use modular budgeting.
• K99/R00 Grant (NIH Pathway to Independence Award) — another NIH mechanism aimed at a specific, narrowly-defined population of investigators/institutions rather than the general applicant pool.
• Grants Management pillar — the broader funding-lifecycle context R15/AREA sits within.

References

• NIH, “Research Enhancement Awards (R15)” — the activity code’s official definition and AREA/REAP structure.
• NIDDK, “R15: Academic Research Enhancement Awards (AREA)” — institutional eligibility, student-composition requirement, and current $375,000/3-year budget terms.
• NIGMS, “Academic Research Enhancement Awards (AREA) (R15)” — institute-level AREA program guidance.
• NIH, PAR-25-134, “Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)” — current active parent announcement; verify budget/eligibility terms here before applying.

Frequently Asked Questions

What does SRC stand for in research?

SRC stands for Scientific Review Committee — an institutional committee that evaluates a research protocol’s scientific merit and feasibility, separately from the ethical review conducted by an Institutional Review Board (IRB).

What happens during SRC review of a protocol?

The SRC evaluates the protocol against criteria such as originality, scientific rationale, study design and methodology, the statistical plan, and feasibility, including whether accrual projections are realistic for the available patient population. Some SRCs also weigh institutional or portfolio prioritization, checking whether the study duplicates or competes with other open protocols for the same patients.

What does SRC approval mean for a clinical trial?

SRC approval means the committee has determined a protocol’s rationale, design, and feasibility are scientifically sound. At NCI-designated cancer centers that follow the standard sequencing, SRC approval is a precondition for submitting the protocol to the IRB, and the trial cannot open to enrollment until it has cleared both reviews.

Is SRC review required for all clinical trials, or only cancer trials?

The SRC requirement is specific to oncology research: NCI-designated cancer centers must maintain a documented scientific-review step as a condition of their Cancer Center Support Grant (CCSG/P30) funding. Outside cancer research, most institutions route protocols directly to the IRB with no separate scientific-review committee in between.

How does SRC review differ from IRB review, and which comes first?

An SRC reviews scientific merit — rationale, design, statistics, and feasibility — while an IRB reviews human-subjects protection, including informed consent, risk-benefit balance, and privacy, under the Common Rule and, for FDA-regulated studies, 21 CFR Part 56. In the NCI model, SRC review comes first: only a protocol the SRC has approved is forwarded to the IRB, so a scientifically weak study can be stopped before it uses IRB review capacity.

What’s the difference between an SRC and a DSMB?

An SRC reviews a protocol’s scientific merit before the study opens, or at periodic checkpoints, making it a one-time or periodic merit gate. A DSMB (or DMC) is a separate, independent body that reviews accumulating trial data — adverse events, efficacy endpoints, and data completeness — at regular intervals after the study has opened, and can recommend continuing, modifying, or stopping the trial.